

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No. SGEN-0051	Application No. 10/522,911
Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
Filing Date July 7, 2005	Group 1654
Confirmation 7034	

U. S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Subclass
/CB/	1 3,445,518	05/1969	Shavel et al.	260	570.8
/CB/	2 4,753,894	06/1998	Frankel et al.	436	548
/CB/	3 4,943,628	07/1990	Rosen et al.	530	326
/CB/	4 5,122,368	06/1992	Greenfield	424	85.1
/CB/	5 5,165,923	11/1992	Thorpe	424	999.999
/CB/	6 5,169,774	12/1992	Frankel et al.	436	240.27
/CB/	7 5,286,637	02/1994	Veronesi et al.	435	183
/CB/	8 5,585,089	12/1996	Queen	424	130.1
/CB/	9 5,629,197	05/1997	Ring et al.	435	240.27
/CB/	10 5,708,146	01/1998	Willner	530	387
/CB/	11 5,714,586	02/1998	Kunstmann et al.	530	391.7
/CB/	12 5,821,337	10/1998	Carter et al.	530	387.3
/CB/	13 5,965,537	10/1999	Ritter	514	17
/CB/	14 6,033,876	03/2000	Lemke	435	69.6
/CB/	15 6,048,720	04/2000	Dalborg et al.	435	219
/CB/	16 6,054,297	04/2000	Carter et al.	435	69.6
/CB/	17 6,054,561	04/2000	Ring	530	388.1
/CB/	18 6,143,721	11/2000	Janssen	514	16
/CB/	19 6,214,345	04/2001	Firestone et al.	424	178.1
/CB/	20 6,323,315	11/2001	Pettit et al.	530	330
/CB/	21 6,342,219	01/2002	Thorpe	424	130.1
/CB/	22 6,407,213	06/2002	Carter et al.	530	387.3

EXAMINER

/Christina Bradley/ (04/22/2008)

DATE CONSIDERED

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
/CB/	23	6,569,834	05/2003	Pettit et al.	514	18
/CB/	24	6,620,911	09/2003	Pettit	517	17
/CB/	25	6,639,055	10/2003	Carter et al.	530	350
/CB/	26	6,884,869	04/2005	Senter et al.	514	17
/CB/	27	6,913,748	07/2005	Widdison	424	1.49
/CB/	28	7,090,843	08/2006	Francisco	424	143.1
/CB/	29	7,091,186	08/2006	Senter et al.	514	27
/CB/	30	7,097,840	08/2006	Erickson et al.	424	178.1
/CB/	31	7,098,305	08/2006	Senter et al.	514	17
/CB/	32	7,098,308	08/2006	Senter et al.	514	17
/CB/	33	2003/0083263	05/2003	Doronina et al.	514	17
/CB/	34	2003/0130189	07/2003	Senter et al.	514	12
/CB/	35	2004/0018194	01/2004	Francisco et al.	424	133.1
/CB/	36	2004/0096392	05/2004	Bhaskar et al.	424	1.11
/CB/	37	2004/0141983	07/2004	Law et al.	424	178.1
/CB/	38	2004/0197325	10/2004	Law et al.	424	131.1
/CB/	39	2004/0235068	11/2004	Levinson	435	7.23
/CB/	40	2005/0014687	01/2005	Anderson et al.	514	12
/CB/	41	2005/0084449	04/2005	Landes	424	1.49
/CB/	42	2005/0106644	05/2005	Caims et al.	424	133.1
/CB/	43	2005/0107595	05/2005	Caims et al.	424	133.1
/CB/	44	2005/0123536	06/2005	Law et al.	424	133.1

EXAMINER /Christina Bradley/ (04/22/2008)**DATE CONSIDERED**

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	

U. S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Subclass
/CB/	45	2005/0180972	08/2005 Wahl et al.	424	133.1
/CB/	46	2005/0238650	10/2005 Crowley et al.	424	178.1
/CB/	47	2005/0238649	10/2005 Doronina	514	17
/CB/	48	2005/0260212	11/2005 Zhang et al.	424	178.1
/CB/	49	2005/0256030	11/2005 Feng	514	2
/CB/	50	2005/0272665	12/2005 Schmid et al.	548	573
/CB/	51	2006/0074008	04/2006 Senter et al.	514	2
/CB/	52	2006/0073152	04/2006 Dennis	424	155.1
/CB/	53	2006/0128970	06/2006 Bliss et al.	548	400
/CB/	54	2006/0233794	10/2006 Che-Leung Law	424	155.1
/CB/	55	2007/0092940	04/2007 Eigenbrot	435	69.1
/CB/	56	2007/0098715	05/2007 Ettenberg et al.	424	143.1
/CB/	57	2007/0160617	07/2007 Ma et al.	424	155.1
/CB/	58	2007/0258987	11/2007 Francisco	424	181.1

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	

FOREIGN PATENT DOCUMENTS						
Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
/CB/	59	CA 2114156	04/1994	CA		
/CB/	60	JP 06234790	08/1994	JP	Abstract Only	
/CB/	61	JP 09077791	03/1997	JP	Abstract Only	
/CB/	62	WO 93/03054	02/1993	PCT	Abstract Only	
/CB/	63	WO 95/09864	04/1995	PCT	Abstract Only	
/CB/	64	WO 96/22384	07/1996	PCT		
/CB/	65	WO 99/35164	07/1999	PCT		
/CB/	66	WO 01/18032	03/2001	PCT		
/CB/	67	WO 02/088172	11/2002	PCT		
/CB/	68	WO 03/008378	01/2003	PCT		
/CB/	69	WO 03/034903	05/2003	PCT		
/CB/	70	WO 03/043583	05/2003	PCT		
/CB/	71	WO 04/32828	04/2004	PCT		
/CB/	72	WO 05/084390	09/2005	PCT		
/CB/	73	WO 2006/071441	07/2006	PCT		
/CB/	74	WO 2006/083936	08/2006	PCT		
/CB/	75	WO 2007/030642	03/2007	PCT		
/CB/	76	WO 2007/070538	06/2007	PCT		
/CB/	77	WO 2007/059082	05/2007	PCT		

EXAMINER	/Christina Bradley/ (04/22/2008)	DATE CONSIDERED
-----------------	----------------------------------	------------------------

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
/CB/	78	WO 2007/109567	09/2007	PCT		
/CB/	79	WO 2007/062138	05/2007	PCT		

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/CB/	80	LAW et al., "CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates," <i>Proceedings of the AACR</i> , volume 45, Abstract # 625, 2004	
/CB/	81	Hamblett et al., "Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate," <i>Proceedings of the AACR</i> , volume 45, Abstract # 624, 2004	
/CB/	82	Senter et al., "Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy," <i>Proceedings of the AACR</i> , volume 45, Abstract # 623, 2004	
/CB/	83	PRESS RELEASE, "Seattle Genetics, Inc. (SGEN) To Present Advances in Preclinical Research At American Cancer Research Annual Meeting," downloaded from internet on August 31, 2004	
/CB/	84	Afar et al., "Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer," <i>Molecular Cancer Therapeutics</i> , 2004, 921-932	
/CB/	85	Bhaskar et al., "E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer," <i>Cancer Research</i> , 2003, 63, 6387-6394	
/CB/	86	Doronina et al., "Development of potent monoclonal antibody auristatin conjugates for cancer therapy," <i>Nature Biotechnology</i> , 2003, 21(7), 778-784	
/CB/	87	Doronina et al., "Errata and Corrigenda," <i>Nature Biotechnology</i> , 2003, 21(8), 941	
/CB/	88	Falini et al., "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," <i>The Lancet</i> , 1992, 339, 1195-1196	
/CB/	89	Fransico et al., "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity," <i>Blood</i> , 2003, 102(4), 1458-1465	
/CB/	90	Frisch et al., "Synthesis of Short Polyoxyethylene-Based Heterobifunctional Cross-Linking Reagents. Application to the Coupling o Peptides to Liposomes," <i>Bioconjugate Chem.</i> , 1996, 7, 180-186	
EXAMINER	/Christina Bradley/ (04/22/2008)		DATE CONSIDERED

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/CB/	91	Gaertner et al., "Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins," <i>Bioconjugate Chem.</i> , 1996, 7, 38-44	
/CB/	92	Genet, J.P., "Recent studies on asymmetric hydrogenation. New catalysts and synthetic applications in organic synthesis," <i>Pure Appl. Chem.</i> , 2002, 74(1), 77-83	
/CB/	93	Aherne et al., "Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay," <i>Cancer Chemother. Pharmacol.</i> , 1996, 38, 225-232	
/CB/	94	Engert et al., "Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease," <i>Cancer Research</i> , 1990, 50, 84-88	
/CB/	95	King et al., "Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates," <i>Bioconjugate Chem.</i> , 1999, 10, 279-288	
/CB/	96	King et al., "Monoclonal Antibody Conjugates of Doxorubicin with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains," <i>J. Med. Chem.</i> , 2002, 45, 4336-4343	
/CB/	97	Kline et al., "Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases-2 and -9," <i>Molecular Pharmaceutics</i> , 2003, 1(1), 9-22	
/CB/	98	Klussman et al., "Secondary mAb-vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome Pathway," <i>Bioconjugate Chem.</i> , 2004, 15, 765-773	
/CB/	99	Mao et al., "EphB2 as a Therapeutic Antibody Drugs target for the Treatment of Colorectal Cancer," <i>Cancer Research</i> , 2004, 64, 781-788	
/CB/	100	May et al., "Evaluation of Ricin a Chain-Containing Immunotoxins Directed Against Different Epitopes On The δ -Chain of Cell Surface-Associated IgD on Murine B Cells," <i>The Journal of Immunology</i> , 1990, 144(9), 3637-3642	

EXAMINER

/Christina Bradley/ (04/22/2008)

DATE CONSIDERED

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/CB/	101	Natsume et al., "Characterization of the Interaction of TZT-1027, a Potent Antitumor Agent, with Tubulin," <i>Jpn. J. Cancer Res.</i> , 2000 , 91, 737-747	
/CB/	102	Pettit et al., "Specific Activites of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans," <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42(11), 2961-2965	
/CB/	103	Pettit et al., "A Cobalt-Phosphine Complex Directed Reformatsky Approach to a stereospecific Synthesis of the Dolastatin 10 Unit Dolaproine (DAP)," <i>J. Org. Chem.</i> , 2001 , 66, 8640-8642	
/CB/	104	Press et al., "Ricin A-Chain Containing Immunotoxins Directed Against Different Epitopes on the CD2 Molecule Differ In Their Ability to Kill Normal and Malignant T Cells," <i>The Journal of Immunology</i> , 1988 , 141(12), 4410-4417	
/CB/	105	Meyer et al., "Chapter 23. Recent Advances In Antibody Drug Conjugates for Cancer Therapy," <i>Annual Reports in Medicinal Chemistry</i> , 2003 , 229-237	
/CB/	106	Schnell et al., "Development Of New Ricin A-Chain Immunotoxins With Potent Anti-Tumor effects Against Human Hodgkin Cells <i>In Vitro</i> And Disseminated Hodgkin Tumors in Scid Mice Using High-Affinity Monoclonal Antibodies Directed Against The CD30 Antigen," <i>Int. J. Cancer</i> , 1995 , 63, 238-244	
/CB/	107	Schöffski et al., "Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer," <i>Annals of Oncology</i> , 2004 , 15, 671-679	
/CB/	108	Doronina et al., "Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy," <i>SciFinder</i> , 2005 , 10 pages	
/CB/	109	Thornber, C.W., "Isoterism and Molecular Modification in Drug Design," <i>Imperial Chemical Industries Limited</i> , downloaded 2007, 563-580	
/CB/	110	Toki et al., "Protease-Mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs," <i>J. Org. Chem.</i> , 2002 , 67, 1866-1872	

EXAMINER /Christina Bradley/ (04/22/2008)

DATE CONSIDERED

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/CB/	111	Trail et al., "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates," <i>Science</i> , 1993 , 261, 212-215	
/CB/	112	Trail et al., "Effect of Linker Variation on the Stability, Potency, and Efficacy of Carcinoma-reactive BR64-Doxorubicin Immunoconjugates," <i>Cancer Research</i> , 1997 , 57, 100-105	
/CB/	113	Tsutsumi et al., "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38(LMB-2) improves Antitumor activity and reduces animal toxicity and immunogenicity," <i>PNAS</i> , 2000 , 97(15), 8548-8553	
/CB/	114	Vippagunta et al., "Crystalline solids," <i>Advanced Drug Delivery Reviews</i> , 2001 , 48, 3-26	
/CB/	115	Woyke et al., "In Vitro Activities and Postantifungal Effects on the Potent Dolastatin 10 Derivative Auristatin PHE," <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45(12), 3580-3584	
/CB/	116	Mohammad et al., "An Orthotopic Model of Human Pancreatic Cancer in Severe Combined Immunodeficient Mice: Potential Application for Preclinical Studies ¹ ," <i>Clinical Cancer Research</i> , 1998 , 4, 887-894	
/CB/	117	Alley et al., "Controlling the location of drug attachment in antibody-drug conjugates," <i>Proceedings of the AACR</i> , 2004 , 45, Abstract #627	
/CB/	118	Carter., "Improving the Efficacy of Antibody-Based Cancer Therapies," <i>Nature Reviews</i> , 1989 , 1, 118-129	
/CB/	119	Dillman., "Monoclonal Antibodies for Treating Cancer," <i>Annals of Internal Medicine</i> , 1989 , 111, 592-603	
/CB/	120	Doronina et al., "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity," <i>Bioconjugate Chem.</i> , 2006 , 17, 114-124	
/CB/	121	Emery et al., "Humanized monoclonal antibodies for therapeutic applications," <i>Exp. Opin. Invest. Drugs</i> , 1994 , 3(3), 241-251	
EXAMINER /Christina Bradley/ (04/22/2008)		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/CB/	122	Inada et al., "Modification of Proteins with Polyethylene Glycol Derivatives," <i>Methods Enzymology</i> , 1994, 242, 65-90	
/CB/	123	Pettit et al., "The Absolute Configuration and Synthesis of Natural (-)-Dolastatin 10," <i>J. Am. Chem. Soc.</i> , 1989, 111, 5463-5465	
/CB/	124	Woyke et al., "Effects of auristatin PHE on micortube integrity and nuclear localization in Cryptococcus neoformans," <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 46(12), 3802-3808	
/CB/	125	In the United States Patent and Trademark Office: Non-Final Rejection Office Action Summary of Application 10/983,340, Dated 10/04/2007, 17 pages	
/CB/	126	In the United States Patent and Trademark Office: Non-Final Rejection Office Action Summary of Application 10/447,257, Dated 04/19/2007, 18 pages	